Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis.

Garcia Garcia de Paredes, Ana; Villanueva, Càndid; Blanco, Carolina; Genescà, Joan; Manicardi, Nicolo; Garcia-Pagan, Juan Carlos; Calleja, Jose Luis; Aracil, Carlos; Morillas, Rosa M; Poca, Maria; Peñas, Beatriz; Augustin, Salvador; Abraldes, Juan G; Alvarado, Eldimar; Royo, Félix; Garcia-Bermejo, Maria Laura; Falcon-Perez, Juan Manuel; Bañares, Rafael; Bosch, Jaime; Gracia-Sancho, Jordi; ... (2021). Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. JHEP reports, 3(6), p. 100368. Elsevier 10.1016/j.jhepr.2021.100368

[img] Text
main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.
Author holds Copyright

Download (346kB) | Request a copy

Background & Aims

Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic response to NSBBs in compensated cirrhosis.

Methods

Serum levels of miR-452-5p, miR-429, miR-885-5p, miR-181b-5p, and miR-122-5p were analyzed in patients with compensated cirrhosis (N = 105). Hepatic venous pressure gradient (HVPG) was measured at baseline, after intravenous propranolol, and 1 year after randomization to NSBBs (n = 52) or placebo (n = 53) (PREDESCI trial). miRNAs were analyzed at baseline and at 1 year.

Results

Nineteen patients (18%) developed ascites, of whom 17 developed ascites after 1 year. miR-181b-5p levels at 1 year, but not at baseline, were higher in patients that developed ascites. The AUC of miR-181b-5p at 1 year to predict ascites was 0.7 (95% CI 0.59-0.78). miR-429 levels were lower at baseline in acute HVPG responders to NSBBs (AUC 0.65; 95% CI, 0.53-0.76), but levels at baseline and at 1 year were not associated with the HVPG response to NSBBs at 1 year.

Conclusions

Serum miR-181b-5p is a promising non-invasive biomarker to identify patients with compensated cirrhosis at risk of ascites development.

Lay summary

Ascites marks the transition from the compensated to decompensated stage in cirrhosis and indicates a worsening in prognosis. There are currently no easily accessible tools to identify patients with compensated cirrhosis at risk of developing ascites. We evaluated the levels of novel molecules termed microRNAs in the blood of patients with compensated cirrhosis and observed that miR-181b-5p can predict which patients are going to develop ascites.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie

UniBE Contributor:

Bosch, Jaime

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2589-5559

Publisher:

Elsevier

Language:

English

Submitter:

Rahel Fuhrer

Date Deposited:

10 Jan 2022 15:42

Last Modified:

16 Jan 2022 01:55

Publisher DOI:

10.1016/j.jhepr.2021.100368

PubMed ID:

34712934

Uncontrolled Keywords:

Ascites CSPH, clinically significant portal hypertension Ct, cycle threshold HVPG, hepatic venous pressure gradient NSBBs, non-selective beta-blockers ROC, receiver-operating characteristic beta-blockers cirrhosis miRNAs, microRNAs microRNA portal hypertension

BORIS DOI:

10.48350/162234

URI:

https://boris.unibe.ch/id/eprint/162234

Actions (login required)

Edit item Edit item
Provide Feedback